Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera

Takefumi Ishii, Edward Bruno, Ronald Hoffman, Mingjiang Xu

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

The JAK2V617FT mutation has been shown to occur in the overwhelming majority of patients with polycythemia vera (PV). To study the role of the mutation in the excessive production of differentiated hematopoietic cells in PV, CD19+, CD3+, CD34+, CD33 +, and glycophorin A+ cells and granulocytes were isolated from the peripheral blood (PB) of 8 patients with PV and 3 healthy donors mobilized with G-CSF, and the percentage of JAK2V617F mutant allele was determined by quantitative real-time polymerase chain reaction (PCR). The JAK2V617F mutation was present in cells belonging to each of the myeloid lineages and was also present in B and T lymphocytes in a subpopulation of patients with PV. The proportion of hematopoietic cells expressing the JAK2V617F mutation decreased after differentiation of CD34 + cells in vitro in the presence of optimal concentrations of SCF, IL-3, IL-6, and Epo. These data suggest that the JAK2V617F mutation may not provide a proliferative and/or survival advantage for the abnormal PV clone. Although the JAK2V617F mutation plays an important role in the biologic origins of PV, it is likely not the sole event leading to PV.

Original languageEnglish (US)
Pages (from-to)3128-3134
Number of pages7
JournalBlood
Volume108
Issue number9
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Glycophorin
Polycythemia Vera
T-cells
Interleukin-3
Polymerase chain reaction
Cell Lineage
Granulocyte Colony-Stimulating Factor
Interleukin-6
Blood
Cells
Mutation
Granulocytes
Real-Time Polymerase Chain Reaction
Cell Differentiation
B-Lymphocytes
Clone Cells
Alleles
Tissue Donors
T-Lymphocytes
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera. / Ishii, Takefumi; Bruno, Edward; Hoffman, Ronald; Xu, Mingjiang.

In: Blood, Vol. 108, No. 9, 01.11.2006, p. 3128-3134.

Research output: Contribution to journalArticle

Ishii, Takefumi ; Bruno, Edward ; Hoffman, Ronald ; Xu, Mingjiang. / Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera. In: Blood. 2006 ; Vol. 108, No. 9. pp. 3128-3134.
@article{0e8020e33629457590b638cbe367e472,
title = "Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera",
abstract = "The JAK2V617FT mutation has been shown to occur in the overwhelming majority of patients with polycythemia vera (PV). To study the role of the mutation in the excessive production of differentiated hematopoietic cells in PV, CD19+, CD3+, CD34+, CD33 +, and glycophorin A+ cells and granulocytes were isolated from the peripheral blood (PB) of 8 patients with PV and 3 healthy donors mobilized with G-CSF, and the percentage of JAK2V617F mutant allele was determined by quantitative real-time polymerase chain reaction (PCR). The JAK2V617F mutation was present in cells belonging to each of the myeloid lineages and was also present in B and T lymphocytes in a subpopulation of patients with PV. The proportion of hematopoietic cells expressing the JAK2V617F mutation decreased after differentiation of CD34 + cells in vitro in the presence of optimal concentrations of SCF, IL-3, IL-6, and Epo. These data suggest that the JAK2V617F mutation may not provide a proliferative and/or survival advantage for the abnormal PV clone. Although the JAK2V617F mutation plays an important role in the biologic origins of PV, it is likely not the sole event leading to PV.",
author = "Takefumi Ishii and Edward Bruno and Ronald Hoffman and Mingjiang Xu",
year = "2006",
month = "11",
day = "1",
doi = "10.1182/blood-2006-04-017392",
language = "English (US)",
volume = "108",
pages = "3128--3134",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera

AU - Ishii, Takefumi

AU - Bruno, Edward

AU - Hoffman, Ronald

AU - Xu, Mingjiang

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The JAK2V617FT mutation has been shown to occur in the overwhelming majority of patients with polycythemia vera (PV). To study the role of the mutation in the excessive production of differentiated hematopoietic cells in PV, CD19+, CD3+, CD34+, CD33 +, and glycophorin A+ cells and granulocytes were isolated from the peripheral blood (PB) of 8 patients with PV and 3 healthy donors mobilized with G-CSF, and the percentage of JAK2V617F mutant allele was determined by quantitative real-time polymerase chain reaction (PCR). The JAK2V617F mutation was present in cells belonging to each of the myeloid lineages and was also present in B and T lymphocytes in a subpopulation of patients with PV. The proportion of hematopoietic cells expressing the JAK2V617F mutation decreased after differentiation of CD34 + cells in vitro in the presence of optimal concentrations of SCF, IL-3, IL-6, and Epo. These data suggest that the JAK2V617F mutation may not provide a proliferative and/or survival advantage for the abnormal PV clone. Although the JAK2V617F mutation plays an important role in the biologic origins of PV, it is likely not the sole event leading to PV.

AB - The JAK2V617FT mutation has been shown to occur in the overwhelming majority of patients with polycythemia vera (PV). To study the role of the mutation in the excessive production of differentiated hematopoietic cells in PV, CD19+, CD3+, CD34+, CD33 +, and glycophorin A+ cells and granulocytes were isolated from the peripheral blood (PB) of 8 patients with PV and 3 healthy donors mobilized with G-CSF, and the percentage of JAK2V617F mutant allele was determined by quantitative real-time polymerase chain reaction (PCR). The JAK2V617F mutation was present in cells belonging to each of the myeloid lineages and was also present in B and T lymphocytes in a subpopulation of patients with PV. The proportion of hematopoietic cells expressing the JAK2V617F mutation decreased after differentiation of CD34 + cells in vitro in the presence of optimal concentrations of SCF, IL-3, IL-6, and Epo. These data suggest that the JAK2V617F mutation may not provide a proliferative and/or survival advantage for the abnormal PV clone. Although the JAK2V617F mutation plays an important role in the biologic origins of PV, it is likely not the sole event leading to PV.

UR - http://www.scopus.com/inward/record.url?scp=33750611344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750611344&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-04-017392

DO - 10.1182/blood-2006-04-017392

M3 - Article

C2 - 16757685

AN - SCOPUS:33750611344

VL - 108

SP - 3128

EP - 3134

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -